Mazdutide — Dosing & Research | Peptide Chats
Research information only. Not medical advice. 18+ only. Not FDA-approved for human therapeutic use.

Mazdutide

Also known as: IBI362, LY3305677, LY3305677, Xinermei

Dual glucagon receptor (GCGR) / glucagon-like peptide-1 receptor (GLP-1R) agonist; incretin-based peptide therapeutic

Research chemicalLast updated: October 19, 2026Based on 23 peer-reviewed studies

What it is

Mazdutide is an investigational weight-loss and diabetes drug being studied in clinical trials, particularly in Asian populations. It activates two hormone pathways at once to cut appetite and burn more calories. Not FDA-approved; Phase 2/3 clinical trials completed or ongoing; in active clinical development.

The scientific side

Mazdutide is a once-weekly dual agonist that simultaneously activates the glucagon-like peptide-1 receptor (GLP-1R) and the glucagon receptor (GCGR). GLP-1R activation stimulates insulin secretion, lowers blood glucose, and reduces appetite. GCGR activation is hypothesized to enhance energy expenditure and stimulate lipolysis and mitochondrial fat oxidation, potentially augmenting weight loss beyond that achieved with GLP-1R monoagonism alone (PMID 41028652, PMID 41478576, PMID 41025406). Preclinical multi-omics analysis in diabetic mice suggests dual GLP-1/GCGR activation engages molecular pathways involved in neuroprotection, energy metabolism, and synaptic plasticity. In animal models of metabolic dysfunction-associated steatotic liver disease (MASLD), mazdutide alleviated endoplasmic reticulum stress via the PERK pathway, suppressed NF-κB-mediated inflammation, and downregulated key lipogenic regulators including SREBP-1, C/EBPβ, and PPARγ. Tubular GCGR signaling has been shown to confer renoprotection in diabetic kidney disease by maintaining V-ATPase (V1-V0) assembly and lysosomal acidification.

Class: Dual glucagon receptor (GCGR) / glucagon-like peptide-1 receptor (GLP-1R) agonist; incretin-based peptide therapeutic

Administration & storage

Administration
Subcutaneous injection once weekly (PMID: 40421736)Subcutaneous injection once weekly (PMID: 41407859)Subcutaneous injection once weekly (PMID: 41407860)Subcutaneous injection once weekly (PMID: 42251595)Subcutaneous injection once weekly (PMID: 41875890)Subcutaneous injection once weekly (PMID: 40832785)Subcutaneous injection once weekly (PMID: 42628555)Subcutaneous injection once weekly (PMID: 35750681)Subcutaneous injection once weekly (PMID: 36247927)Subcutaneous injection (every 3 days in animal modelPMID: 40828048)
Storage
Storage conditions for mazdutide are not described in the reviewed abstracts.
Cautions
Gastrointestinal adverse events (nausea, vomiting, diarrhea, decreased appetite) are the most commonly reported treatment-emergent adverse events across clinical trials, and are generally mild to moderate in severity (PMID: 40421736, PMID: 41407859, PMID: 41407860, PMID: 42251595).,Treatment discontinuation due to adverse events occurred in up to 20% of participants receiving the 16 mg dose in one phase 2 trial, primarily due to gastrointestinal disorders.,Cardiovascular considerations: GCGR/GLP-1R dual agonists, including mazdutide, may increase heart rate to a similar extent as GLP-1R monoagonists; cardiovascular outcomes trial data are not yet available for mazdutide.,Evidence for mazdutide in adolescents is limited to a single case report; no randomized controlled trial data in pediatric populations were identified.,Data on long-term (beyond 60 weeks) cardiovascular safety, mortality, and multi-ethnic generalizability are currently lacking; most trials were conducted in Chinese adults.,Sterile technique is required for subcutaneous injection to minimize infection risk.

Legal & regulatory status

US FDA

Not stated in reviewed literature — requires manual verification

WADA

Not stated in reviewed literature — requires manual verification

Health Canada

Not stated in reviewed literature — requires manual verification